ArriVent BioPharma (NASDAQ:AVBP) Trading Up 8.4% - Here's Why

Key Points

• Shares of ArriVent BioPharma jumped about 8.4% to roughly $22.78 on Tuesday, trading on far lower-than-average volume (78,112 vs. avg. 492,013 shares).
• Analyst sentiment is broadly positive—multiple firms initiated or raised coverage with targets from $33 to $50, leaving a consensus rating of “Moderate Buy” and an average price target of $41.67.
• The clinical-stage company (market cap ≈ $1.03 billion) is advancing targeted lung-cancer therapies including Furmonertinib (phase 3 trials); it reported a Q1 EPS of -$0.78 (beat estimates) but is projected to post -2.74 EPS for the year.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report)'s stock price shot up 8.4% during trading on Tuesday . The stock traded as high as $22.55 and last traded at $22.7820. 78,112 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 492,013 shares. The stock had previously closed at $21.01.

Analyst Ratings Changes

A number of analysts have issued reports on the company. BTIG Research assumed coverage on ArriVent BioPharma in a report on Thursday, March 12th. They set a "buy" rating and a $42.00 price target for the company. Citigroup raised their target price on ArriVent BioPharma from $31.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Cantor Fitzgerald assumed coverage on ArriVent BioPharma in a research note on Monday, December 22nd. They set an "overweight" rating for the company. Oppenheimer reaffirmed an "outperform" rating and issued a $50.00 price target (up from $44.00) on shares of ArriVent BioPharma in a report on Friday, March 6th. Finally, B. Riley Financial increased their price target on shares of ArriVent BioPharma from $37.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $41.67.

ArriVent BioPharma Stock Up 11.3%

The stock has a market capitalization of $1.03 billion, a PE ratio of -5.32 and a beta of 0.98. The business's 50-day moving average is $23.01 and its two-hundred day moving average is $21.35.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its earnings results on Thursday, March 5th. The company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.09. As a group, analysts anticipate that ArriVent BioPharma, Inc. will post -2.74 EPS for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVBP. AIHC Capital Management Ltd purchased a new position in shares of ArriVent BioPharma during the fourth quarter worth approximately $12,973,000. Vanguard Group Inc. raised its position in ArriVent BioPharma by 36.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,029,531 shares of the company's stock valued at $37,445,000 after purchasing an additional 545,991 shares during the last quarter. Fund 1 Investments LLC acquired a new stake in ArriVent BioPharma during the 2nd quarter worth $11,503,000. UBS Group AG grew its position in ArriVent BioPharma by 474.7% during the 3rd quarter. UBS Group AG now owns 497,601 shares of the company's stock worth $9,181,000 after purchasing an additional 411,013 shares during the last quarter. Finally, Suvretta Capital Management LLC increased its stake in ArriVent BioPharma by 10.9% in the fourth quarter. Suvretta Capital Management LLC now owns 4,106,035 shares of the company's stock valued at $82,613,000 after purchasing an additional 402,583 shares during the period. Hedge funds and other institutional investors own 9.48% of the company's stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.